Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1549–1559. doi: 10.1158/1078-0432.CCR-21-4049

Figure 3: PSA and radiographic progression free survival.

Figure 3:

A. Kaplan-Meier plot of time to PSA progression while receiving Enz alone compared with Enz+Mif after combination dosing began at 12 weeks, showing a median progression-free survival hazard ratio of 1.09 comparing both arms (log rank p=0.83).

B. Kaplan-Meier plot of time to radiographic progression. After a 12-week Enz lead-in, patients were randomized to receive either Enz alone or Enz+Mif, showing a median progression-free survival of NR in Enz alone arm and 16.5m in Enz+Mif arm (p=0.22).

Abbreviations: Enz, Enzalutamide; Enz alone, Enz 160mg daily after 12-week enzalutamide monotherapy lead in; Enz+Mif, Enz 120mg and Mif 300 mg daily after 12 week Enz lead-in; Mif, Mifepristone; PSA, prostate specific antigen